Cargando…

Evolution of Bordetella pertussis in the acellular vaccine era in Norway, 1996 to 2019

We described the population structure of Bordetella pertussis (B. pertussis) in Norway from 1996 to 2019 and determined if there were evolutionary shifts and whether these correlated with changes in the childhood immunization program. We selected 180 B. pertussis isolates, 22 from the whole cell vac...

Descripción completa

Detalles Bibliográficos
Autores principales: Brandal, Lin T., Vestrheim, Didrik F., Bruvik, Torbjørn, Roness, Ragnhild B., Bjørnstad, Martha L., Greve-Isdahl, Margrethe, Steens, Anneke, Brynildsrud, Ola B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135841/
https://www.ncbi.nlm.nih.gov/pubmed/35543837
http://dx.doi.org/10.1007/s10096-022-04453-0
_version_ 1784714051384770560
author Brandal, Lin T.
Vestrheim, Didrik F.
Bruvik, Torbjørn
Roness, Ragnhild B.
Bjørnstad, Martha L.
Greve-Isdahl, Margrethe
Steens, Anneke
Brynildsrud, Ola B.
author_facet Brandal, Lin T.
Vestrheim, Didrik F.
Bruvik, Torbjørn
Roness, Ragnhild B.
Bjørnstad, Martha L.
Greve-Isdahl, Margrethe
Steens, Anneke
Brynildsrud, Ola B.
author_sort Brandal, Lin T.
collection PubMed
description We described the population structure of Bordetella pertussis (B. pertussis) in Norway from 1996 to 2019 and determined if there were evolutionary shifts and whether these correlated with changes in the childhood immunization program. We selected 180 B. pertussis isolates, 22 from the whole cell vaccine (WCV) era (1996–1997) and 158 from the acellular vaccine (ACV) era (1998–2019). We conducted whole genome sequencing and determined the distribution and frequency of allelic variants and temporal changes of ACV genes. Norwegian B. pertussis isolates were evenly distributed across a phylogenetic tree that included global strains. We identified seven different allelic profiles of ACV genes (A–F), in which profiles A1, A2, and B dominated (89%), all having pertussis toxin (ptxA) allele 1, pertussis toxin promoter (ptxP) allele 3, and pertactin (prn) allele 2 present. Isolates with ptxP1 and prn1 were not detected after 2007, whereas the prn2 allele likely emerged prior to 1972, and ptxP3 before the early 1980s. Allele conversions of ACV genes all occurred prior to the introduction of ACV. Sixteen percent of our isolates showed mutations within the prn gene. ACV and its booster doses (implemented for children in 2007 and adolescents in 2013) might have contributed to evolvement of a more uniform B. pertussis population, with recent circulating strains having ptxA1, ptxP3, and prn2 present, and an increasing number of prn mutations. These strains clearly deviate from ACV strains (ptxA1, ptxP1, prn1), and this could have implications for vaccine efficiency and, therefore, prevention and control of pertussis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10096-022-04453-0.
format Online
Article
Text
id pubmed-9135841
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-91358412022-05-28 Evolution of Bordetella pertussis in the acellular vaccine era in Norway, 1996 to 2019 Brandal, Lin T. Vestrheim, Didrik F. Bruvik, Torbjørn Roness, Ragnhild B. Bjørnstad, Martha L. Greve-Isdahl, Margrethe Steens, Anneke Brynildsrud, Ola B. Eur J Clin Microbiol Infect Dis Original Article We described the population structure of Bordetella pertussis (B. pertussis) in Norway from 1996 to 2019 and determined if there were evolutionary shifts and whether these correlated with changes in the childhood immunization program. We selected 180 B. pertussis isolates, 22 from the whole cell vaccine (WCV) era (1996–1997) and 158 from the acellular vaccine (ACV) era (1998–2019). We conducted whole genome sequencing and determined the distribution and frequency of allelic variants and temporal changes of ACV genes. Norwegian B. pertussis isolates were evenly distributed across a phylogenetic tree that included global strains. We identified seven different allelic profiles of ACV genes (A–F), in which profiles A1, A2, and B dominated (89%), all having pertussis toxin (ptxA) allele 1, pertussis toxin promoter (ptxP) allele 3, and pertactin (prn) allele 2 present. Isolates with ptxP1 and prn1 were not detected after 2007, whereas the prn2 allele likely emerged prior to 1972, and ptxP3 before the early 1980s. Allele conversions of ACV genes all occurred prior to the introduction of ACV. Sixteen percent of our isolates showed mutations within the prn gene. ACV and its booster doses (implemented for children in 2007 and adolescents in 2013) might have contributed to evolvement of a more uniform B. pertussis population, with recent circulating strains having ptxA1, ptxP3, and prn2 present, and an increasing number of prn mutations. These strains clearly deviate from ACV strains (ptxA1, ptxP1, prn1), and this could have implications for vaccine efficiency and, therefore, prevention and control of pertussis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10096-022-04453-0. Springer Berlin Heidelberg 2022-05-11 2022 /pmc/articles/PMC9135841/ /pubmed/35543837 http://dx.doi.org/10.1007/s10096-022-04453-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Brandal, Lin T.
Vestrheim, Didrik F.
Bruvik, Torbjørn
Roness, Ragnhild B.
Bjørnstad, Martha L.
Greve-Isdahl, Margrethe
Steens, Anneke
Brynildsrud, Ola B.
Evolution of Bordetella pertussis in the acellular vaccine era in Norway, 1996 to 2019
title Evolution of Bordetella pertussis in the acellular vaccine era in Norway, 1996 to 2019
title_full Evolution of Bordetella pertussis in the acellular vaccine era in Norway, 1996 to 2019
title_fullStr Evolution of Bordetella pertussis in the acellular vaccine era in Norway, 1996 to 2019
title_full_unstemmed Evolution of Bordetella pertussis in the acellular vaccine era in Norway, 1996 to 2019
title_short Evolution of Bordetella pertussis in the acellular vaccine era in Norway, 1996 to 2019
title_sort evolution of bordetella pertussis in the acellular vaccine era in norway, 1996 to 2019
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135841/
https://www.ncbi.nlm.nih.gov/pubmed/35543837
http://dx.doi.org/10.1007/s10096-022-04453-0
work_keys_str_mv AT brandallint evolutionofbordetellapertussisintheacellularvaccineerainnorway1996to2019
AT vestrheimdidrikf evolutionofbordetellapertussisintheacellularvaccineerainnorway1996to2019
AT bruviktorbjørn evolutionofbordetellapertussisintheacellularvaccineerainnorway1996to2019
AT ronessragnhildb evolutionofbordetellapertussisintheacellularvaccineerainnorway1996to2019
AT bjørnstadmarthal evolutionofbordetellapertussisintheacellularvaccineerainnorway1996to2019
AT greveisdahlmargrethe evolutionofbordetellapertussisintheacellularvaccineerainnorway1996to2019
AT steensanneke evolutionofbordetellapertussisintheacellularvaccineerainnorway1996to2019
AT brynildsrudolab evolutionofbordetellapertussisintheacellularvaccineerainnorway1996to2019